FindTrial
Sign In

MT-ND6 in primary membranous nephropathy

Downregulation of MT-ND6 expression in podocyte mitochondria mediates dysfunction of complex I and participates in the pathogenesis of primary membranous nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109206
Enrollment
Unknown
Registered
2025-09-15
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Membranous nephropathy

Interventions

Control:NA
MN:NA

Sponsors

The Affiliated Hospital of Yunnan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for the Membranous Nephropathy Group: 1. Diagnosed with idiopathic membranous nephropathy (IMN) through renal biopsy, meeting the Ehrenreich-Churg pathological staging criteria; 2. Age >=18 years and =18 years and <=65 years; 3. Complete clinical data.

Exclusion criteria

Exclusion criteria: Exclusion criteria for membranous nephropathy group: 1. Secondary MN (such as SLE, HBV infection, related to malignant tumors); 2. Coexisting other primary glomerular diseases (such as IgA nephropathy); 3. Renal biopsy showing less than 10 glomeruli or incomplete pathological data; 4. Pregnant or breastfeeding women; 5. Coexisting other potentially life-threatening diseases; Exclusion criteria for normal control group: 1. No indications for surgical treatment of the kidney.

Design outcomes

Primary

MeasureTime frame
mt-nd6;—

Countries

China

Contacts

Public ContactYin Zhao

The Affiliated Hospital of Yunnan University

zhyinyx@126.com+86 871 65156776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026